{"gene":"GNAO1","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2000,"finding":"Gαo is required for the light response of ON bipolar neurons in the retina. In Gαo-null mice, the b-wave of the electroretinogram (representing massed ON bipolar cell responses) was entirely absent, while rod/cone photocurrents (a-wave) were normal, establishing that mGluR6 cascade signaling in ON bipolar cells requires Gαo.","method":"Knockout mouse (Gαo-/-), electroretinogram recording","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO mouse with specific cellular phenotype (ERG b-wave loss), replicated across rod- and cone-driven components","pmids":["11124982"],"is_preprint":false},{"year":1997,"finding":"Gαo is required for muscarinic inhibition of L-type Ca2+ channels in ventricular myocytes. Gαo-null mice lack muscarinic inhibition of L-type calcium channels, while isoproterenol stimulation and muscarinic regulation of atrial K+ channels remain normal. Other Gα subunits cannot substitute.","method":"Homologous recombination knockout mouse, patch-clamp electrophysiology of ventricular myocytes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO mouse, specific electrophysiological phenotype with appropriate controls showing other G proteins unchanged","pmids":["9050846"],"is_preprint":false},{"year":1994,"finding":"Gαo (but not Gαq/11 or Gαi1-3) transduces α-adrenoceptor inhibition of Ca2+ current in rat sympathetic (superior cervical ganglion) neurons, as established by microinjection of selective anti-Gαo antibodies which reduced noradrenaline-induced calcium current inhibition.","method":"Intraneuronal microinjection of subunit-specific antibodies, electrophysiology","journal":"The Journal of physiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — antibody microinjection with subunit-selective reagents and appropriate controls for other Gα subunits","pmids":["7932231"],"is_preprint":false},{"year":2000,"finding":"Gαo is a direct target of reactive oxygen species (H2O2): H2O2 directly activates purified heterotrimeric Go (but not Gs) in vitro by modifying Gαo (not Gβγ), causing subunit dissociation and liberating free Gβγ, which then activates ERK via PI3K and Src in cardiomyocytes.","method":"In vitro GTPγS binding assay with purified Go, subunit-specific analysis, cardiomyocyte signaling assays, Gβγ inhibition","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct biochemical reconstitution with purified protein plus multiple cellular assays showing Gβγ-dependent ERK activation downstream of Gαo modification by ROS","pmids":["11100733"],"is_preprint":false},{"year":2001,"finding":"The N-terminus of Gαo binds to the C-terminus of the α1A (P/Q-type, Cav2.1) Ca2+ channel subunit, and this interaction mediates voltage-resistant inhibition of α1A currents. An anti-Gαo N-terminal antiserum, Gαo N-terminal peptide, and α1A C-terminal peptide all attenuated voltage-resistant inhibition, and in vitro binding was demonstrated.","method":"In vitro binding assay, peptide competition, antibody inhibition, electrophysiology","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro binding reconstitution with peptide competition plus functional electrophysiology in same study; single lab but multiple orthogonal methods","pmids":["11395521"],"is_preprint":false},{"year":2011,"finding":"Gαo is required for vomeronasal sensory neuron function in V2R receptor-expressing (basal layer) neurons. Conditional Gαo deletion from olfactory marker protein-expressing cells eliminated responses to MHC class I antigens, major urinary proteins, exocrine gland-secreting peptide, and N-formylated mitochondrial peptides. Loss of Gαo also abolished male-male territorial aggression and maternal aggression.","method":"Cre-loxP conditional knockout, electrophysiology, calcium imaging, behavioral assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with direct electrophysiology and calcium imaging plus behavioral readouts; multiple orthogonal methods","pmids":["21768373"],"is_preprint":false},{"year":2005,"finding":"Gαo/i reduces the stability of Rap1GAPII by targeting it for ubiquitination and proteasomal degradation, thereby activating Rap1 and inducing neurite outgrowth downstream of CB1 cannabinoid receptor activation. Proteasomal inhibitor lactacystin blocked Gαo/i-induced Rap1 activation and neurite outgrowth.","method":"Dominant-negative Rap1 expression, proteasomal inhibition, siRNA, pertussis toxin treatment, overexpression in Neuro-2A cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal interventions (PTX, lactacystin, siRNA, DN-Rap1) in same study establishing mechanism","pmids":["15657046"],"is_preprint":false},{"year":2005,"finding":"CB1 receptor signaling through Gαo/i sequentially activates Rap1 → Ral → Src → Stat3, and also Rac1 → JNK → Stat3, to induce neurite outgrowth in Neuro-2A cells. Dominant-negative constructs of Rap1, Ral, Src, and Stat3 each blocked CB1R-induced neurite outgrowth; Ral-DN blocked Gαo-induced Stat3 activation but not v-Src-induced Stat3 activation.","method":"Dominant-negative mutant overexpression, pharmacological inhibitors (SP600125), kinase phosphorylation assays, pertussis toxin","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple DN constructs and inhibitors defining pathway order, single lab","pmids":["16046413"],"is_preprint":false},{"year":2008,"finding":"Gαo is required for WNT3a-induced JNK activation in mammalian cells, operating downstream of Frizzled-1 through Dishevelled-1 and Dishevelled-3 (not Dvl-2), and then through RhoA, Rac1, Cdc42, and MEKK1/MEKK4 to JNK. This is distinct from the WNT-β-catenin pathway that requires both Gαo and Gαq.","method":"siRNA knockdown epistasis, Dapper1 (Dvl antagonist) expression, dominant-negative small GTPases, chemical inhibitors (SP600125, SB203580), F9 teratocarcinoma cells","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Moderate — systematic epistasis experiments with siRNA and DN mutants establishing pathway order; single lab, multiple orthogonal methods","pmids":["18187455"],"is_preprint":false},{"year":2011,"finding":"The oncogenic R243H mutation in Gαo renders it constitutively active by accelerating the rate of GDP-to-GTP nucleotide exchange without impairing GTPase activity or GAP sensitivity. The mechanism involves loss of an electrostatic interaction between R243 and E43 in the P-loop. Constitutively active Gαo R243H enhances Src-STAT3 signaling in NIH-3T3 cells.","method":"Limited proteolysis assays, nucleotide-binding assays, single-turnover and steady-state GTPase assays, structural analysis, Src-STAT3 signaling readouts in cells","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple in vitro enzymatic assays (nucleotide binding, GTPase) plus structural analysis and cell-based signaling; single lab but orthogonal biochemical methods","pmids":["21317923"],"is_preprint":false},{"year":2022,"finding":"Three common GNAO1 encephalopathy mutations affecting Gly203, Arg209, and Glu246 accelerate GTP uptake and inactivate GTP hydrolysis by displacing Gln205, resulting in constitutive GTP binding. The mutant Gαo proteins fail to adopt the active conformation and display aberrant interactions with signaling partners. Zn2+ restores GTPase activity and cellular interactions of these mutants without affecting wild-type Gαo. Dietary zinc rescues motor function and longevity in a Drosophila GNAO1 encephalopathy model.","method":"GTP uptake/hydrolysis assays, high-throughput drug screening, Drosophila in vivo model, biochemical interaction assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro biochemical assays for GTP binding/hydrolysis combined with cellular interaction studies and in vivo Drosophila rescue; multiple orthogonal methods","pmids":["36206333"],"is_preprint":false},{"year":2013,"finding":"De novo mutations in GNAO1 cause epileptic encephalopathy. Mutations predicted to destabilize Gαo fold showed impaired plasma membrane localization. The Gly203Arg substitution (switch II region) impairs GTP binding and/or downstream effector activation. Gαo-mediated inhibition of calcium currents by norepinephrine was reduced in three of four mutants by electrophysiological analysis.","method":"Whole-exome sequencing, 3D structural modeling, transient expression with localization studies, electrophysiological analysis of Ca2+ current inhibition","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — structural modeling combined with cellular localization assays and electrophysiology; multiple approaches but structural predictions computational","pmids":["23993195"],"is_preprint":false},{"year":2003,"finding":"Gγ13 is coexpressed with Gαo (Gαomicron), Gβ3, and Gβ4 specifically in retinal ON bipolar cells (not OFF bipolar cells), suggesting this specific heterotrimer composition participates in ON bipolar cell signal transduction.","method":"Immunohistochemistry, single-cell PCR with cDNA hybridization, transgenic GFP mouse to identify bipolar cell types, patch-clamp confirmation of ON physiology","journal":"The Journal of comparative neurology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-localization by IHC and single-cell PCR in defined cell types; functional link inferred from co-expression rather than direct functional experiment","pmids":["12454992"],"is_preprint":false},{"year":1996,"finding":"Gαo and Gαi2 are expressed in separate subsets of VNO sensory neurons and are both enriched in VNO microvilli (the transduction compartment), suggesting involvement in pheromone sensory transduction. Adenylyl cyclase type II is co-expressed in both subsets.","method":"Cloning, in situ hybridization, immunohistochemistry in mouse VNO","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — localization by IHC with subcellular enrichment shown, but functional link is inferential; later confirmed by conditional KO study (PMID 21768373)","pmids":["8558259"],"is_preprint":false},{"year":1995,"finding":"Voltage-dependent calcium channel β-subunit, in combination with α1 subunits, has a GTPase-activating effect on Gαo in rat frontal cortex membranes. Anti-β-subunit antiserum abolished (-)-BayK 8644-stimulated GTP hydrolysis by Go, and a peptide mimicking the β-subunit binding domain of the channel complex also attenuated this GTPase activation.","method":"GTPase assay in cortical membranes, antibody inhibition, peptide competition, dihydropyridine binding","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical GTPase assay in native membranes with antibody and peptide competition; single lab, two approaches","pmids":["7544301"],"is_preprint":false},{"year":2000,"finding":"Mu-opioid receptor co-immunoprecipitates with Gαo, Gαi1, and Gαi3 (and to a lesser extent Gαi2) from solubilized rat brain membranes. GTPγS treatment abolished co-immunoprecipitation, indicating the receptor associates with these G proteins in the GDP-bound (inactive) heterotrimer state.","method":"Co-immunoprecipitation from solubilized rat brain, [3H]DAMGO binding, GTPγS sensitivity","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — reciprocal co-IP from native tissue with nucleotide sensitivity control; single method","pmids":["10693938"],"is_preprint":false},{"year":2017,"finding":"GNAO1 mutations display two distinct functional classes: loss-of-function (LOF, <90% maximal cAMP inhibition) and gain-of-function (GOF, lower EC50 for α2A adrenergic receptor-mediated cAMP inhibition). LOF mutations correlate with epileptic encephalopathy while GOF mutations (G42R, G203R, E246K) and normally-functioning mutants associate with movement disorders.","method":"Site-directed mutagenesis, Western blot for protein expression, cAMP inhibition assay in HEK-293T cells co-expressing α2A-adrenergic receptor","journal":"Neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cAMP assay across 15 clinical variants with defined readout; single lab but systematic coverage","pmids":["28747448"],"is_preprint":false},{"year":2020,"finding":"Gαo interacts with SPTAN1 (α-spectrin, another DEE-associated protein) as identified by co-immunoprecipitation and mass spectrometry. Silencing of Gnao1 attenuated neurite outgrowth and calcium-dependent signaling. GNAO1-deficient brain organoids showed reduced SPTAN1 and Ankyrin-G expression and failed to conduct synchronized firing.","method":"Co-immunoprecipitation, mass spectrometry, siRNA knockdown, iPSC-derived brain organoids, calcium imaging, neuronal activity recording","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP/MS identification of binding partner combined with functional KD phenotype; single lab, multiple readouts","pmids":["33107105"],"is_preprint":false},{"year":2008,"finding":"Cardiac-specific expression of constitutively active Gαo1* in transgenic mice enhances contractile function, increases L-type Ca2+ channel current density, Ca2+ transients, and cell shortening. Protein phosphatase 1 activity was reduced in Gαo* ventricles and PKA-site phosphorylation of ryanodine receptor and phospholamban was increased, suggesting Gαo* acts via protein phosphatase 1 rather than PKA/cAMP.","method":"Transgenic mouse cardiac-specific expression, in vivo cardiac function, patch-clamp electrophysiology, Ca2+ transient measurements, protein phosphatase activity assay, PKA assay, cAMP measurement","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic mouse with constitutively active protein and multiple mechanistic readouts; single lab","pmids":["18192223"],"is_preprint":false},{"year":2002,"finding":"In C. elegans, the N-terminal region of RGS protein EGL-10 determines selective inhibition of GOA-1 (Gαo) vs. EGL-30 (Gαq). The N-terminal fragment localizes to membrane where it complexes with the GGL/RGS fragment via GPB-2 (Gβ subunit), increasing the GGL/RGS fragment abundance and membrane localization. Chimera experiments showed GGL/RGS domain of either RGS can act on either Gα, with the N-terminal region determining selectivity.","method":"C. elegans transgenic chimera expression, co-immunoprecipitation, fractionation, in vivo phenotypic assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis with chimeric transgenes plus biochemical co-IP and fractionation; C. elegans GOA-1 is the GNAO1 ortholog","pmids":["12354761"],"is_preprint":false},{"year":2021,"finding":"GNAO1 mutations at Gln52 (Gαo[Gln52Pro] and novel Gαo[Gln52Arg]) are deficient in GTP binding and hydrolysis. At the cellular level, the mutants show defective interaction with partner proteins that recognize GDP-loaded or GTP-loaded Gαo, and plasma membrane localization is strongly reduced while Golgi localization persists.","method":"Biochemical GTP binding/hydrolysis assays, cellular interaction assays, subcellular fractionation/imaging","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro enzymatic assays combined with cellular localization studies; single lab","pmids":["34685729"],"is_preprint":false},{"year":2024,"finding":"Pathogenic GNAO1 mutants gain neomorphic interactions with both Ric8A and Ric8B chaperones, relocalizing them from cytoplasm to Golgi. Normally, Ric8A chaperones Gαi/Gαo/Gαq/Gα12/Gα13 and Ric8B solely chaperones Gαs/Gαolf. Pathogenic mutants show abnormal GTP uptake/hydrolysis, reduced Gβγ and RGS19 interactions, and reduced plasma membrane localization. Strength of Gαo-Ric8B interaction correlates with clinical disease severity.","method":"Co-immunoprecipitation, GTP binding/hydrolysis assays, cellular localization imaging, clinical severity correlation","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic characterization of >80 mutants with biochemical and cell biological methods, multiple orthogonal approaches, clinical correlation; rigorous single lab study","pmids":["38874642"],"is_preprint":false},{"year":2022,"finding":"GNAO1 G203R and G42R mutations produce strong loss-of-function defects when evaluated as homozygous CRISPR alleles in C. elegans, and also produce dominant-negative effects in heterozygous animals and transgenic overexpression. Experiments in mice confirmed dominant-negative effects of GNAO1 G42R on multiple motor behaviors.","method":"CRISPR/Cas9 knockin in C. elegans, transgenic overexpression, heterozygous allele analysis, mouse motor behavioral assays","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR knockin in two model organisms with defined behavioral readouts; single lab","pmids":["34508586"],"is_preprint":false},{"year":2022,"finding":"C. elegans goa-1 (GNAO1 ortholog) mutants exhibit excessive neurotransmitter release (hypersensitivity to aldicarb) and hyperactive locomotion. Caffeine rescues aberrant motor function primarily through adenosine receptor antagonism.","method":"CRISPR/Cas9 knockin in C. elegans, aldicarb assay, automated locomotion analysis, pharmacological rescue with caffeine and selective A2A receptor antagonist istradefylline","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR knockin with defined neurotransmitter release readout and pharmacological dissection; single lab","pmids":["34622282"],"is_preprint":false},{"year":2021,"finding":"GNAO1 knockdown reduces Gnao1 expression in the locus coeruleus of morphine-dependent mice, and antisense oligonucleotide-mediated knockdown of Gnao1 reduced naloxone-precipitated withdrawal jumping in B6 mice, establishing a functional role for Gαo in opioid physical dependence.","method":"Antisense oligonucleotide knockdown, quantitative PCR, behavioral naloxone-precipitated withdrawal assay in recombinant congenic mouse strains","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antisense knockdown with behavioral functional readout and strain-specific controls; single lab","pmids":["19460419"],"is_preprint":false},{"year":2024,"finding":"Gαo negatively regulates Schwann cell differentiation and myelination in the peripheral nervous system. Schwann cell-specific Gnao1 deletion promotes SC differentiation, accelerates remyelination after nerve injury, and increases cAMP and PI3K/AKT activity. Conversely, Gnao1 overexpression in SCs impairs myelination.","method":"Schwann cell-specific conditional KO, Gnao1 overexpression transgenic mice, nerve injury/remyelination assay, cAMP measurement, PI3K/AKT signaling, RNA sequencing","journal":"Acta neuropathologica communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO and overexpression with mechanistic pathway analysis; single lab","pmids":["38331815"],"is_preprint":false},{"year":2021,"finding":"NRSF transcriptionally represses cardiac Gαo (Gnao1) expression. Increased cardiac Gαo in NRSF-knockout mice leads to increased surface sarcolemmal L-type Ca2+ channel activity, CaMKII activation, impaired Ca2+ handling, and cardiac dysfunction. Cardiac-specific Gnao1 overexpression alone is sufficient to induce cardiac dysfunction; conversely, Gnao1 knockdown ameliorated dysfunction in heart failure models.","method":"Cardiac-specific NRSF-KO mice, dominant-negative NRSF transgenic mice, Gnao1 cardiac-specific overexpression and knockdown, cardiac function measurements, L-type Ca2+ channel activity, CaMKII signaling assays","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain and loss of function in multiple mouse models with mechanistic pathway analysis (L-type Ca2+ channel, CaMKII); multiple orthogonal approaches","pmids":["34875852"],"is_preprint":false},{"year":1995,"finding":"The phenotypic differences in GDP affinity and activated conformation between Gαo and Gαi2 upon C-terminal truncation are determined by the N-terminal portion of the protein (upstream of codon 212). Chimera analysis and deletion studies identified three hydrophobic residues (positions 11-13 from C-terminus) that make contact with the N-terminal regions (start of β-strands 1 and 3) to stabilize the C-terminal α-helix and affect nucleotide binding.","method":"In vitro synthesis in rabbit reticulocyte lysate, tryptic proteolysis assay for conformation, Gαo/Gαi2 chimeras using conserved BamHI site, GDP/GTP binding assays","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with chimeras and mutagenesis; single lab, multiple biochemical readouts","pmids":["7727415"],"is_preprint":false},{"year":2001,"finding":"The C-terminal -3 position glycine residue of Gαo is critical for productive interaction with and activation by the α2A-adrenoceptor. Mutating this Gly to Glu (as in Gαs) drastically reduced agonist potency (22-150 fold) and altered agonist efficacy at the receptor, demonstrating that the C-terminal -3 position of Gαo constrains a structure favorable for receptor interaction.","method":"Site-directed mutagenesis of Gαo C-terminus, [35S]GTPγS binding assay in Sf9 cells expressing α2A-AR, pertussis toxin resistance analysis, receptor binding assays","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — mutagenesis with functional GTP binding assay and receptor affinity measurements; single lab","pmids":["11562427"],"is_preprint":false},{"year":2014,"finding":"A gain-of-function knock-in mouse (Gnao1+/G184S), carrying a RGS-insensitive mutation that prevents Go GTPase turnoff by RGS proteins, develops rare seizures, increased interictal epileptiform discharges, and strain-dependent premature death. This establishes that constitutive Gαo activation (failure to turn off) contributes to seizure susceptibility.","method":"Genomic knock-in mouse, EEG recording, pentylenetetrazol kindling, genetic modifier mapping","journal":"Mammalian genome","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knock-in mouse model with EEG phenotyping; single lab, defined gain-of-function mechanism (RGS insensitivity)","pmids":["24700286"],"is_preprint":false},{"year":2024,"finding":"Leu→Pro substitutions in the N-terminal α-helix of Gαo (L13P and L23P) uniquely destabilize the N-terminal α-helix, block formation of the heterotrimeric G-protein, and disable activation by GPCRs, without affecting enzymatic activity or overall folding. This is associated with a parkinsonism phenotype distinct from the hyperkinetic movement disorder seen with other GNAO1 mutations.","method":"Structural and biochemical analysis of purified mutant proteins, heterotrimer formation assay, GPCR coupling assay, clinical phenotyping","journal":"Movement disorders","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical characterization of purified mutant protein with structural analysis and functional GPCR coupling assay; single lab","pmids":["38358016"],"is_preprint":false},{"year":2023,"finding":"An intronic GNAO1 mutation (c.724-8G>A) creates a novel splice acceptor site causing in-frame 6-bp intronic retention (2 amino acid insertion, Pro-Gln) within the switch III region of Gαo. This insertion misconfigures switch III, creating novel interactions with switch II, resulting in increased GTP uptake, defective GTP hydrolysis, and aberrant effector protein interactions, while Gβγ interactions and GPCR coupling remain unchanged.","method":"RNA splicing analysis from patient lymphoblastoid cells, molecular biochemical characterization (GTP uptake/hydrolysis), protein interaction assays","journal":"Med (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — splice analysis from patient cells with mechanistic biochemical characterization; single lab, multiple assays","pmids":["37001522"],"is_preprint":false},{"year":2022,"finding":"The intronic GNAO1 c.724-8G>A variant causes an in-frame 2 amino acid insertion (Thr241_Asn242insProGln) in Gαo. The mutant protein shows no significant difference in expression levels but displays partially shifted localization to the cytoplasm compared to exclusive membrane localization of wild-type Gαo.","method":"RNA extraction from patient lymphoblastoid cells, immunoblotting, immunostaining of transfected cells","journal":"Neurogenetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, immunostaining for localization without full functional follow-up","pmids":["35147852"],"is_preprint":false},{"year":2024,"finding":"siRNA-mediated depletion of Gnao1 in Neuro2a cells perturbs expression of transcripts associated with Rho GTPase signaling and impairs neurite outgrowth. The G203R variant of Gαo disables growth cone formation in iPSC-derived cortical neurons and disrupts neuro-spherical assembly and phospho-MLC2 polarity in cortical organoids. Rho kinase inhibitor Y27632 restores these morphological phenotypes, placing Gαo upstream of the Rho-ROCK pathway in neuronal morphogenesis.","method":"siRNA knockdown, iPSC-derived cortical neurons and organoids from patient with G203R variant, immunofluorescence for growth cone markers and phospho-MLC2, pharmacological rescue with Y27632","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD in cell line plus patient-derived iPSC model with pharmacological rescue defining pathway; single lab","pmids":["39048611"],"is_preprint":false},{"year":1998,"finding":"Human substance P receptor (hSPR) directly activates Gαo (as well as Gαq/11 and Gαs) in CHO cells, as demonstrated by photoaffinity labeling of Gα subunits with [32P]AA-GTP upon hSPR stimulation followed by subunit-specific immunoprecipitation.","method":"Photoaffinity labeling with [32P]azidoanilido-GTP, subunit-specific immunoprecipitation","journal":"FEBS letters","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single photoaffinity labeling experiment; single lab, single method","pmids":["9654151"],"is_preprint":false},{"year":1989,"finding":"Five pertussis toxin-sensitive G proteins were purified from bovine brain including two Gαo isoforms (Gαo-I and Gαo-II) with distinct peptide mapping profiles and migration rates. Only Gαo-I is present in NG 108-15 cell membranes.","method":"Protein purification, immunochemical characterization, in situ peptide mapping, PAGE","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct protein purification and biochemical characterization of two Gαo isoforms; single study","pmids":["2506013"],"is_preprint":false},{"year":1996,"finding":"ADP-ribosylation by pertussis toxin (IAP) of Gαo occurs at the C-terminal cysteine residue of Gαo, causing conformational changes as evidenced by enhanced immunoreactivity to C-terminal (but not N-terminal) antibodies and increased sensitivity to trypsin proteolysis. The kinetics of Gi/Go ADP-ribosylation parallel the rate of loss of coupling between inhibitory neuroreceptors and adenylyl cyclase.","method":"Cholera toxin/IAP ADP-ribosylation in pituitary cells, antibody immunoreactivity assays, trypsin proteolysis, adenylyl cyclase coupling kinetics","journal":"Journal of receptor and signal transduction research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — indirect conformational evidence from antibody epitope accessibility; single lab","pmids":["8897310"],"is_preprint":false},{"year":2021,"finding":"The GNAO1 R209C mutation in ALL increases GTPase activity and promotes cell proliferation and neoplastic transformation. Combined with ETV6-RUNX1 fusion, R209C activates PI3K/Akt/mTOR signaling. mTORC1 phosphorylates p300 acetyltransferase, which acetylates ETV6-RUNX1 and enhances its transcriptional activity on the GNAO1 R209C promoter, forming a positive feedback loop.","method":"Ectopic expression in cell lines, cell proliferation assay, transformation assay, PI3K/Akt/mTOR pathway analysis, p300 phosphorylation/acetylation assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cell-based assays establishing signaling pathway; single lab, oncology context","pmids":["32898863"],"is_preprint":false}],"current_model":"Gαo (encoded by GNAO1) is the most abundant G protein α-subunit in the mammalian brain and is the immediate signal transducer downstream of multiple GPCRs; it mediates inhibition of neuronal N- and L-type Ca2+ channels (via both direct N-terminal interaction with the Cav2.1 C-terminus and Gβγ-dependent mechanisms), couples mGluR6 to ON bipolar cell light responses in the retina, transduces pheromone detection via V2R receptors in the VNO, mediates WNT-JNK planar cell polarity signaling through Dvl1/3 → RhoA/Rac1/Cdc42 → MEKK1/4 → JNK, and promotes neurite outgrowth by targeting Rap1GAPII for proteasomal degradation to activate Rap1 → Ral → Src → Stat3; it is a target of oxidative stress (ROS directly modify Gαo to cause subunit dissociation), negatively regulates Schwann cell myelination by suppressing cAMP and PI3K/AKT, regulates cardiac Ca2+ homeostasis downstream of NRSF, and is regulated by RGS proteins that act as GTPase-activating proteins (GAPs); pathogenic de novo mutations in GNAO1 disrupt GTP binding/hydrolysis, impair plasma membrane localization, and gain neomorphic interactions with Ric8 chaperones, causing a spectrum of pediatric encephalopathies ranging from epileptic encephalopathy (loss-of-function mutations) to hyperkinetic movement disorders (gain-of-function mutations)."},"narrative":{"mechanistic_narrative":"GNAO1 encodes Gαo, a pertussis toxin-sensitive heterotrimeric G protein α-subunit that serves as the immediate transducer downstream of numerous neuronal GPCRs and couples receptor activation to ion-channel and cytoskeletal control [PMID:7932231, PMID:10693938]. As a guanine-nucleotide switch, Gαo cycles between GDP-bound (receptor-associated, inactive heterotrimer) and GTP-bound active states; its nucleotide-binding conformation is governed by the N-terminal region and switch elements, and its C-terminal -3 glycine constrains productive receptor coupling [PMID:7727415, PMID:11562427]. In sensory and neuronal circuits Gαo is functionally non-redundant: it is required for the mGluR6-driven light response of retinal ON bipolar cells [PMID:11124982], for V2R-receptor-mediated vomeronasal pheromone detection and associated aggression behaviors [PMID:21768373], and for muscarinic and α-adrenergic inhibition of neuronal and cardiac Ca2+ channels, in part through direct N-terminal binding to the Cav2.1 C-terminus [PMID:9050846, PMID:7932231, PMID:11395521]. Beyond channel modulation, Gαo drives morphogenetic signaling—promoting neurite outgrowth by targeting Rap1GAPII for proteasomal degradation to activate a Rap1→Ral→Src→Stat3 cascade and a parallel Rho-GTPase→JNK arm downstream of CB1 and WNT/Frizzled receptors [PMID:15657046, PMID:16046413, PMID:18187455], and acting upstream of Rho-ROCK to control growth-cone formation and neuronal polarity [PMID:39048611]. Gαo also negatively regulates Schwann cell myelination by suppressing cAMP and PI3K/AKT [PMID:38331815] and sets cardiac Ca2+ homeostasis as a transcriptional target of NRSF [PMID:34875852]. Its GTPase cycle is accelerated by RGS proteins acting as GAPs [PMID:12354761, PMID:24700286], and the protein is a direct oxidative-stress sensor, with H2O2 modifying Gαo to drive subunit dissociation and Gβγ-dependent ERK activation [PMID:11100733]. De novo GNAO1 mutations cause a spectrum of pediatric encephalopathies: loss-of-function alleles that impair plasma-membrane localization and receptor-mediated cAMP/Ca2+ signaling associate with epileptic encephalopathy, whereas gain-of-function and conformation-altering alleles—which accelerate GTP uptake, abolish hydrolysis by displacing the catalytic glutamine, and acquire neomorphic interactions with Ric8 chaperones—associate with hyperkinetic movement disorders, with disease severity correlating with the strength of aberrant Gαo-Ric8B binding [PMID:23993195, PMID:28747448, PMID:36206333, PMID:38874642]. Distinct N-terminal helix-destabilizing substitutions that block heterotrimer formation produce a parkinsonian phenotype [PMID:38358016].","teleology":[{"year":1989,"claim":"Established that Gαo exists as biochemically distinct purifiable isoforms in brain, providing the protein substrate for all subsequent functional work.","evidence":"Protein purification and peptide mapping of two Gαo isoforms from bovine brain","pmids":["2506013"],"confidence":"Medium","gaps":["Functional differences between Gαo-I and Gαo-II not resolved","Tissue distribution of isoforms incomplete"]},{"year":1995,"claim":"Defined how the nucleotide-binding conformation of Gαo is structurally encoded, showing the N-terminal region and specific hydrophobic C-terminal contacts govern GDP affinity and the activated state.","evidence":"In vitro chimera and deletion analysis of Gαo/Gαi2 with proteolysis and nucleotide-binding assays","pmids":["7727415"],"confidence":"Medium","gaps":["No high-resolution structure of the full switch cycle","Did not address GPCR coupling determinants"]},{"year":1997,"claim":"Demonstrated that Gαo is the non-redundant transducer of receptor-mediated Ca2+ channel inhibition, ruling out substitution by other Gα subunits.","evidence":"Gαo-null mouse with patch-clamp of ventricular myocytes and sympathetic neuron antibody microinjection","pmids":["9050846","7932231"],"confidence":"High","gaps":["Molecular basis of channel inhibition (direct vs Gβγ) not distinguished here","Effector identity downstream of Gαo unresolved"]},{"year":2000,"claim":"Resolved Gαo's roles in a sensory circuit and as a direct redox sensor, showing it is required for the ON bipolar light response and is activated by H2O2 to liberate signaling Gβγ.","evidence":"Gαo-null ERG recordings; in vitro GTPγS binding with purified Go plus cardiomyocyte ERK assays","pmids":["11124982","11100733"],"confidence":"High","gaps":["Site of oxidative modification on Gαo not mapped","Link between retinal requirement and downstream effectors incomplete"]},{"year":2001,"claim":"Identified a direct physical mechanism for channel modulation and a structural determinant of receptor coupling, mapping Gαo N-terminus to the Cav2.1 C-terminus and the C-terminal -3 glycine to α2A-adrenoceptor activation.","evidence":"In vitro binding, peptide competition, electrophysiology, and C-terminal mutagenesis with GTPγS binding","pmids":["11395521","11562427"],"confidence":"High","gaps":["Stoichiometry of Gαo-Cav2.1 binding unknown","Generality across channel subtypes untested"]},{"year":2005,"claim":"Defined a morphogenetic effector pathway, showing Gαo induces neurite outgrowth by degrading Rap1GAPII to activate a Rap1→Ral→Src→Stat3 cascade with a parallel Rac1/JNK arm.","evidence":"Dominant-negative constructs, proteasome and pathway inhibitors, siRNA, pertussis toxin in Neuro-2A cells","pmids":["15657046","16046413"],"confidence":"High","gaps":["Mechanism by which Gαo directs Rap1GAPII ubiquitination unknown","Relevance to in vivo neuronal development not tested here"]},{"year":2008,"claim":"Placed Gαo in WNT planar-cell-polarity signaling and cardiac contractile control, defining a Frizzled→Dvl1/3→RhoA/Rac1/Cdc42→MEKK→JNK axis and a constitutively active cardiac phenotype.","evidence":"siRNA epistasis with DN GTPases in F9 cells; cardiac-specific constitutively active Gαo1* transgenic mice","pmids":["18187455","18192223"],"confidence":"High","gaps":["Direct Gαo-Dishevelled interaction not biochemically demonstrated","PP1 versus PKA contributions in heart only partially separated"]},{"year":2011,"claim":"Confirmed the inferred sensory role in vivo and provided the first disease-relevant activating mutation, with conditional KO eliminating V2R responses and the R243H oncogenic mutant accelerating nucleotide exchange.","evidence":"Cre-loxP conditional KO with electrophysiology/behavior; limited proteolysis and GTPase assays with structural analysis","pmids":["21768373","21317923"],"confidence":"High","gaps":["VNO transduction effectors downstream of Gαo unmapped","R243H tumor spectrum and physiological relevance limited"]},{"year":2013,"claim":"Established GNAO1 as a Mendelian encephalopathy gene, linking de novo mutations to impaired membrane localization and reduced receptor-mediated Ca2+ current inhibition.","evidence":"Whole-exome sequencing, 3D modeling, localization and electrophysiology of transfected mutants","pmids":["23993195"],"confidence":"Medium","gaps":["Structural predictions were computational","Genotype-phenotype mapping incomplete at this stage"]},{"year":2017,"claim":"Provided a functional dichotomy underlying clinical heterogeneity, separating loss-of-function (epilepsy) from gain-of-function (movement disorder) GNAO1 variants by cAMP inhibition phenotype.","evidence":"Systematic site-directed mutagenesis and cAMP inhibition assays across 15 variants in HEK-293T cells","pmids":["28747448"],"confidence":"Medium","gaps":["Single signaling readout (cAMP) used to classify","Mechanism for normally-functioning mutants causing disease unexplained"]},{"year":2021,"claim":"Extended mechanistic and physiological scope, defining nucleotide-binding defects and mislocalization for Gln52 mutants, an oncogenic R209C PI3K/mTOR feedback loop, and roles in opioid dependence and NRSF-controlled cardiac Ca2+ handling.","evidence":"Biochemical GTP assays and localization; cell transformation and signaling assays; antisense KD with withdrawal behavior; cardiac NRSF-KO and Gnao1 gain/loss mouse models","pmids":["34685729","32898863","19460419","34875852"],"confidence":"Medium","gaps":["Partner proteins distinguishing GDP- vs GTP-loaded Gαo not all identified","Causal chain from cardiac Gαo to CaMKII activation partly correlative"]},{"year":2022,"claim":"Unified the biochemical and organismal basis of encephalopathy mutations and revealed therapeutic entry points, showing Gln205 displacement causes constitutive GTP binding, dominant-negative behavior in vivo, and rescue by zinc or adenosine-receptor antagonism.","evidence":"GTP uptake/hydrolysis assays, drug screening, Drosophila zinc rescue, C. elegans CRISPR knock-ins, mouse behavior, aldicarb assays","pmids":["36206333","34508586","34622282"],"confidence":"Medium","gaps":["Aberrant partner interactions only partially characterized","Mechanism of zinc rescue at atomic resolution unresolved"]},{"year":2023,"claim":"Defined how a non-coding GNAO1 mutation produces disease, showing an intronic splice variant inserts two residues into switch III to misconfigure the GTPase machinery while sparing Gβγ and GPCR coupling.","evidence":"Patient lymphoblastoid splicing analysis with biochemical GTP and interaction assays","pmids":["37001522"],"confidence":"Medium","gaps":["Specific effector interactions altered not fully enumerated","In vivo consequences not modeled"]},{"year":2024,"claim":"Converged on a neomorphic disease mechanism and refined neuronal and movement-disorder pathophysiology, showing mutant Gαo gains aberrant Ric8A/Ric8B chaperone interactions correlating with severity, acts upstream of Rho-ROCK in neuronal morphogenesis, and produces parkinsonism via heterotrimer-disrupting N-helix substitutions.","evidence":"Co-IP of >80 mutants with localization and clinical correlation; iPSC neurons/organoids with Y27632 rescue; biochemical analysis of purified N-helix mutants; Schwann cell conditional KO","pmids":["38874642","39048611","38358016","38331815"],"confidence":"High","gaps":["How neomorphic Ric8 binding translates to specific clinical features unclear","Therapeutic targeting of mutant-Ric8 interaction untested"]},{"year":null,"claim":"It remains unresolved how the diverse loss-of-function, gain-of-function, dominant-negative, and neomorphic biochemical defects map onto the distinct clinical phenotypes (epilepsy, hyperkinetic movement disorder, parkinsonism) and which downstream effector imbalance is the proximate driver of each.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking specific effector dysregulation to each phenotype","Cell-type-specific consequences of mutations not systematically mapped","No demonstrated mutation-targeted therapy in patients"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[9,10,14,27,37]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,2,15,28,34]},{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[3]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,6,26]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[11,20,21,32]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[20,21]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[21,32]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2,5,8,15]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[0,5,6,33]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[11,16,21,30,37]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,7,25,33]}],"complexes":["heterotrimeric Go (Gαo/Gβ/Gγ)"],"partners":["CAV2.1","RGS19","RIC8A","RIC8B","SPTAN1","DVL1","DVL3","GNB3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P09471","full_name":"Guanine nucleotide-binding protein G(o) subunit alpha","aliases":[],"length_aa":354,"mass_kda":40.1,"function":"Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades (PubMed:29925951, PubMed:33408414). The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state (By similarity). Signaling by an activated GPCR promotes GDP release and GTP binding (By similarity). The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal (By similarity). Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins (By similarity). Signaling is mediated via effector proteins, such as adenylate cyclase (By similarity). Inhibits adenylate cyclase activity, leading to decreased intracellular cAMP levels (By similarity)","subcellular_location":"Cell membrane; Membrane","url":"https://www.uniprot.org/uniprotkb/P09471/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GNAO1","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GNAO1","total_profiled":1310},"omim":[{"mim_id":"619344","title":"PURKINJE CELL PROTEIN 2; PCP2","url":"https://www.omim.org/entry/619344"},{"mim_id":"617493","title":"NEURODEVELOPMENTAL DISORDER WITH INVOLUNTARY MOVEMENTS; NEDIM","url":"https://www.omim.org/entry/617493"},{"mim_id":"617098","title":"RIBONUCLEASE K; RNASEK","url":"https://www.omim.org/entry/617098"},{"mim_id":"615473","title":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 17; DEE17","url":"https://www.omim.org/entry/615473"},{"mim_id":"611240","title":"GPRIN FAMILY, MEMBER 2; GPRIN2","url":"https://www.omim.org/entry/611240"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":133.2},{"tissue":"retina","ntpm":48.0}],"url":"https://www.proteinatlas.org/search/GNAO1"},"hgnc":{"alias_symbol":["G-ALPHA-o"],"prev_symbol":[]},"alphafold":{"accession":"P09471","domains":[{"cath_id":"3.40.50.300","chopping":"37-60_182-191_199-338","consensus_level":"high","plddt":96.3627,"start":37,"end":338},{"cath_id":"1.10.400.10","chopping":"62-169","consensus_level":"high","plddt":97.5153,"start":62,"end":169}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P09471","model_url":"https://alphafold.ebi.ac.uk/files/AF-P09471-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P09471-F1-predicted_aligned_error_v6.png","plddt_mean":94.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GNAO1","jax_strain_url":"https://www.jax.org/strain/search?query=GNAO1"},"sequence":{"accession":"P09471","fasta_url":"https://rest.uniprot.org/uniprotkb/P09471.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P09471/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P09471"}},"corpus_meta":[{"pmid":"8558259","id":"PMC_8558259","title":"Sensory transduction in vomeronasal neurons: evidence for G alpha o, G alpha i2, and adenylyl cyclase II as major components of a pheromone signaling cascade.","date":"1996","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/8558259","citation_count":254,"is_preprint":false},{"pmid":"11100733","id":"PMC_11100733","title":"G alpha(i) and G alpha(o) are target proteins of reactive oxygen species.","date":"2000","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11100733","citation_count":220,"is_preprint":false},{"pmid":"23993195","id":"PMC_23993195","title":"De Novo mutations in GNAO1, encoding a Gαo subunit of heterotrimeric G proteins, cause epileptic encephalopathy.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23993195","citation_count":191,"is_preprint":false},{"pmid":"11124982","id":"PMC_11124982","title":"The light response of ON bipolar neurons requires G[alpha]o.","date":"2000","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11124982","citation_count":164,"is_preprint":false},{"pmid":"21768373","id":"PMC_21768373","title":"G protein G(alpha)o is essential for vomeronasal function and aggressive behavior in mice.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21768373","citation_count":147,"is_preprint":false},{"pmid":"7932231","id":"PMC_7932231","title":"Muscarinic M-current inhibition via G alpha q/11 and alpha-adrenoceptor inhibition of Ca2+ current via G alpha o in rat sympathetic neurones.","date":"1994","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/7932231","citation_count":130,"is_preprint":false},{"pmid":"9050846","id":"PMC_9050846","title":"G alpha(o) is necessary for muscarinic regulation of Ca2+ channels in mouse heart.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9050846","citation_count":113,"is_preprint":false},{"pmid":"15657046","id":"PMC_15657046","title":"Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/i-triggered proteasomal degradation of Rap1GAPII.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15657046","citation_count":107,"is_preprint":false},{"pmid":"12454992","id":"PMC_12454992","title":"G protein subunit G gamma 13 is coexpressed with G alpha o, G beta 3, and G beta 4 in retinal ON bipolar cells.","date":"2003","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12454992","citation_count":105,"is_preprint":false},{"pmid":"28747448","id":"PMC_28747448","title":"Movement disorder in GNAO1 encephalopathy associated with gain-of-function mutations.","date":"2017","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28747448","citation_count":92,"is_preprint":false},{"pmid":"16046413","id":"PMC_16046413","title":"The G alpha(o/i)-coupled cannabinoid receptor-mediated neurite outgrowth involves Rap regulation of Src and Stat3.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16046413","citation_count":92,"is_preprint":false},{"pmid":"12642378","id":"PMC_12642378","title":"Functional coupling of the human dopamine D2 receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity.","date":"2003","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12642378","citation_count":75,"is_preprint":false},{"pmid":"18187455","id":"PMC_18187455","title":"G alpha o mediates WNT-JNK signaling through dishevelled 1 and 3, RhoA family members, and MEKK 1 and 4 in mammalian cells.","date":"2008","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/18187455","citation_count":70,"is_preprint":false},{"pmid":"30103967","id":"PMC_30103967","title":"Deep brain stimulation is effective in pediatric patients with GNAO1 associated severe hyperkinesia.","date":"2018","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30103967","citation_count":62,"is_preprint":false},{"pmid":"29758257","id":"PMC_29758257","title":"A mechanistic review on GNAO1-associated movement disorder.","date":"2018","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29758257","citation_count":61,"is_preprint":false},{"pmid":"30682224","id":"PMC_30682224","title":"Spectrum of neurodevelopmental disease associated with the GNAO1 guanosine triphosphate-binding region.","date":"2019","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/30682224","citation_count":57,"is_preprint":false},{"pmid":"26060304","id":"PMC_26060304","title":"Progressive Movement Disorder in Brothers Carrying a GNAO1 Mutation Responsive to Deep Brain Stimulation.","date":"2015","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26060304","citation_count":57,"is_preprint":false},{"pmid":"21317923","id":"PMC_21317923","title":"Molecular basis of a novel oncogenic mutation in GNAO1.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21317923","citation_count":55,"is_preprint":false},{"pmid":"35722775","id":"PMC_35722775","title":"Highlighting the Dystonic Phenotype Related to GNAO1.","date":"2022","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/35722775","citation_count":53,"is_preprint":false},{"pmid":"10693938","id":"PMC_10693938","title":"Immunoprecipitation of high-affinity, guanine nucleotide-sensitive, solubilized mu-opioid receptors from rat brain: coimmunoprecipitation of the G proteins G(alpha o), G(alpha i1), and G(alpha i3).","date":"2000","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10693938","citation_count":47,"is_preprint":false},{"pmid":"9654151","id":"PMC_9654151","title":"Human substance P receptor expressed in Chinese hamster ovary cells directly activates G(alpha q/11), G(alpha s), G(alpha o).","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9654151","citation_count":44,"is_preprint":false},{"pmid":"7544301","id":"PMC_7544301","title":"Voltage-dependent calcium channel beta-subunits in combination with alpha 1 subunits, have a GTPase activating effect to promote the hydrolysis of GTP by G alpha o in rat frontal cortex.","date":"1995","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/7544301","citation_count":44,"is_preprint":false},{"pmid":"36206333","id":"PMC_36206333","title":"Restoration of the GTPase activity and cellular interactions of Gαo mutants by Zn2+ in GNAO1 encephalopathy models.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36206333","citation_count":42,"is_preprint":false},{"pmid":"27625011","id":"PMC_27625011","title":"Recurrent GNAO1 Mutations Associated With Developmental Delay and a Movement Disorder.","date":"2016","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27625011","citation_count":40,"is_preprint":false},{"pmid":"7727415","id":"PMC_7727415","title":"Interactions between the amino- and carboxyl-terminal regions of G alpha subunits: analysis of mutated G alpha o/G alpha i2 chimeras.","date":"1995","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7727415","citation_count":39,"is_preprint":false},{"pmid":"30987631","id":"PMC_30987631","title":"Genes CEP55, FOXD3, FOXF2, GNAO1, GRIA4, and KCNA5 as potential diagnostic biomarkers in colorectal cancer.","date":"2019","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/30987631","citation_count":38,"is_preprint":false},{"pmid":"9415716","id":"PMC_9415716","title":"Role of G alpha q or G alpha o proteins in alpha 1-adrenoceptor subtype-mediated responses in Fischer 344 rat aorta.","date":"1997","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9415716","citation_count":38,"is_preprint":false},{"pmid":"34622282","id":"PMC_34622282","title":"Caenorhabditis elegans provides an efficient drug screening platform for GNAO1-related disorders and highlights the potential role of caffeine in controlling dyskinesia.","date":"2022","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34622282","citation_count":37,"is_preprint":false},{"pmid":"12354761","id":"PMC_12354761","title":"An N-terminal region of Caenorhabditis elegans RGS proteins EGL-10 and EAT-16 directs inhibition of G(alpha)o versus G(alpha)q signaling.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12354761","citation_count":37,"is_preprint":false},{"pmid":"24700286","id":"PMC_24700286","title":"Gain-of-function mutation in Gnao1: a murine model of epileptiform encephalopathy (EIEE17)?","date":"2014","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/24700286","citation_count":35,"is_preprint":false},{"pmid":"37548038","id":"PMC_37548038","title":"Severity of GNAO1-Related Disorder Correlates with Changes in G-Protein Function.","date":"2023","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37548038","citation_count":34,"is_preprint":false},{"pmid":"33107105","id":"PMC_33107105","title":"GNAO1 organizes the cytoskeletal remodeling and firing of developing neurons.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/33107105","citation_count":34,"is_preprint":false},{"pmid":"27072799","id":"PMC_27072799","title":"GNAO1 encephalopathy: further delineation of a severe neurodevelopmental syndrome affecting females.","date":"2016","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/27072799","citation_count":34,"is_preprint":false},{"pmid":"28202424","id":"PMC_28202424","title":"GNAO1-associated epileptic encephalopathy and movement disorders: c.607G>A variant represents a probable mutation hotspot with a distinct phenotype.","date":"2017","source":"Epileptic disorders : international epilepsy journal with videotape","url":"https://pubmed.ncbi.nlm.nih.gov/28202424","citation_count":32,"is_preprint":false},{"pmid":"35090564","id":"PMC_35090564","title":"Mouse models characterize GNAO1 encephalopathy as a neurodevelopmental disorder leading to motor anomalies: from a severe G203R to a milder C215Y mutation.","date":"2022","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/35090564","citation_count":32,"is_preprint":false},{"pmid":"2118945","id":"PMC_2118945","title":"Pretreatment of mouse striatal neurons in primary culture with 17 beta-estradiol enhances the pertussis toxin-catalyzed ADP-ribosylation of G alpha o,i protein subunits.","date":"1990","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2118945","citation_count":32,"is_preprint":false},{"pmid":"34508586","id":"PMC_34508586","title":"Genetic modeling of GNAO1 disorder delineates mechanisms of Gαo dysfunction.","date":"2022","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34508586","citation_count":31,"is_preprint":false},{"pmid":"31076915","id":"PMC_31076915","title":"Long-term effect of subthalamic and pallidal deep brain stimulation for status dystonicus in children with methylmalonic acidemia and GNAO1 mutation.","date":"2019","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/31076915","citation_count":31,"is_preprint":false},{"pmid":"29661126","id":"PMC_29661126","title":"GNAO1 Mutation-Induced Pediatric Dystonic Storm Rescue With Pallidal Deep Brain Stimulation.","date":"2018","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29661126","citation_count":30,"is_preprint":false},{"pmid":"8458398","id":"PMC_8458398","title":"In situ hybridization reveals specific increases in G alpha s and G alpha o mRNA in discrete brain regions of morphine-tolerant rats.","date":"1993","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8458398","citation_count":30,"is_preprint":false},{"pmid":"34685729","id":"PMC_34685729","title":"Pediatric Encephalopathy: Clinical, Biochemical and Cellular Insights into the Role of Gln52 of GNAO1 and GNAI1 for the Dominant Disease.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34685729","citation_count":27,"is_preprint":false},{"pmid":"26485252","id":"PMC_26485252","title":"Clinical whole-exome sequencing reveals a novel missense pathogenic variant of GNAO1 in a patient with infantile-onset epilepsy.","date":"2015","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26485252","citation_count":27,"is_preprint":false},{"pmid":"31907305","id":"PMC_31907305","title":"Mice with GNAO1 R209H Movement Disorder Variant Display Hyperlocomotion Alleviated by Risperidone.","date":"2020","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/31907305","citation_count":25,"is_preprint":false},{"pmid":"27916449","id":"PMC_27916449","title":"A case of severe movement disorder with GNAO1 mutation responsive to topiramate.","date":"2017","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/27916449","citation_count":24,"is_preprint":false},{"pmid":"2506013","id":"PMC_2506013","title":"Purification and characterization of subforms of the guanine-nucleotide-binding proteins G alpha i and G alpha o.","date":"1989","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2506013","citation_count":24,"is_preprint":false},{"pmid":"32898863","id":"PMC_32898863","title":"Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32898863","citation_count":21,"is_preprint":false},{"pmid":"11395521","id":"PMC_11395521","title":"Binding of G alpha(o) N terminus is responsible for the voltage-resistant inhibition of alpha(1A) (P/Q-type, Ca(v)2.1) Ca(2+) channels.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11395521","citation_count":21,"is_preprint":false},{"pmid":"33036271","id":"PMC_33036271","title":"Humanization of Drosophila Gαo to Model GNAO1 Paediatric Encephalopathies.","date":"2020","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/33036271","citation_count":20,"is_preprint":false},{"pmid":"28503590","id":"PMC_28503590","title":"Clinical Phenotype of De Novo GNAO1 Mutation: Case Report and Review of Literature.","date":"2015","source":"Child neurology open","url":"https://pubmed.ncbi.nlm.nih.gov/28503590","citation_count":20,"is_preprint":false},{"pmid":"19460419","id":"PMC_19460419","title":"Gnao1 (G alphaO protein) is a likely genetic contributor to variation in physical dependence on opioids in mice.","date":"2009","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19460419","citation_count":19,"is_preprint":false},{"pmid":"34122306","id":"PMC_34122306","title":"Phenotypes of GNAO1 Variants in a Chinese Cohort.","date":"2021","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34122306","citation_count":19,"is_preprint":false},{"pmid":"38874642","id":"PMC_38874642","title":"Neomorphic Gαo mutations gain interaction with Ric8 proteins in GNAO1 encephalopathies.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38874642","citation_count":18,"is_preprint":false},{"pmid":"38903163","id":"PMC_38903163","title":"Dyskinetic crisis in GNAO1-related disorders: clinical perspectives and management strategies.","date":"2024","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38903163","citation_count":18,"is_preprint":false},{"pmid":"23984917","id":"PMC_23984917","title":"The down-regulation of GNAO1 and its promoting role in hepatocellular carcinoma.","date":"2013","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/23984917","citation_count":18,"is_preprint":false},{"pmid":"9606722","id":"PMC_9606722","title":"Inactivation of the G alpha i2 and G alpha o genes by homologous recombination.","date":"1997","source":"Receptors & channels","url":"https://pubmed.ncbi.nlm.nih.gov/9606722","citation_count":17,"is_preprint":false},{"pmid":"7493405","id":"PMC_7493405","title":"Developmental expression of G alpha o and G alpha s isoforms in PC12 cells: relationship to neurite outgrowth.","date":"1995","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/7493405","citation_count":17,"is_preprint":false},{"pmid":"38881224","id":"PMC_38881224","title":"Clinical and Molecular Profiling in GNAO1 Permits Phenotype-Genotype Correlation.","date":"2024","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/38881224","citation_count":16,"is_preprint":false},{"pmid":"40225165","id":"PMC_40225165","title":"Phenotypic Diversity in GNAO1 Patients: A Comprehensive Overview of Variants and Phenotypes.","date":"2023","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/40225165","citation_count":16,"is_preprint":false},{"pmid":"36833246","id":"PMC_36833246","title":"Phenotypic Assessment of Pathogenic Variants in GNAO1 and Response to Caffeine in C. elegans Models of the Disease.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36833246","citation_count":16,"is_preprint":false},{"pmid":"39153472","id":"PMC_39153472","title":"Zinc for GNAO1 encephalopathy: Preclinical profiling and a clinical case.","date":"2024","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/39153472","citation_count":14,"is_preprint":false},{"pmid":"30682176","id":"PMC_30682176","title":"Mouse models of GNAO1-associated movement disorder: Allele- and sex-specific differences in phenotypes.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30682176","citation_count":14,"is_preprint":false},{"pmid":"24549219","id":"PMC_24549219","title":"Comprehensive pathway-based analysis identifies associations of BCL2, GNAO1 and CHD2 with non-obstructive azoospermia risk.","date":"2014","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24549219","citation_count":14,"is_preprint":false},{"pmid":"27515449","id":"PMC_27515449","title":"Toll-like receptor 2-mediated MAPKs and NF-κB activation requires the GNAO1-dependent pathway in human mast cells.","date":"2016","source":"Integrative biology : quantitative biosciences from nano to macro","url":"https://pubmed.ncbi.nlm.nih.gov/27515449","citation_count":14,"is_preprint":false},{"pmid":"37999699","id":"PMC_37999699","title":"Deep Brain Stimulation for GNAO1-Associated Dystonia: A Systematic Review and Meta-Analysis.","date":"2023","source":"Neuromodulation : journal of the International Neuromodulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/37999699","citation_count":13,"is_preprint":false},{"pmid":"34875852","id":"PMC_34875852","title":"NRSF-GNAO1 Pathway Contributes to the Regulation of Cardiac Ca2+ Homeostasis.","date":"2021","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/34875852","citation_count":13,"is_preprint":false},{"pmid":"38434323","id":"PMC_38434323","title":"Cortical neurons obtained from patient-derived iPSCs with GNAO1 p.G203R variant show altered differentiation and functional properties.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/38434323","citation_count":13,"is_preprint":false},{"pmid":"37001522","id":"PMC_37001522","title":"In-depth molecular profiling of an intronic GNAO1 mutant as the basis for personalized high-throughput drug screening.","date":"2023","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37001522","citation_count":13,"is_preprint":false},{"pmid":"29709639","id":"PMC_29709639","title":"DNMT1 mediated promoter methylation of GNAO1 in hepatoma carcinoma cells.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/29709639","citation_count":13,"is_preprint":false},{"pmid":"35080448","id":"PMC_35080448","title":"Mice with monoallelic GNAO1 loss exhibit reduced inhibitory synaptic input to cerebellar Purkinje cells.","date":"2022","source":"Journal of neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/35080448","citation_count":12,"is_preprint":false},{"pmid":"34441836","id":"PMC_34441836","title":"Cognitive Assessment in GNAO1 Neurodevelopmental Disorder Using an Eye Tracking System.","date":"2021","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34441836","citation_count":12,"is_preprint":false},{"pmid":"2512386","id":"PMC_2512386","title":"Distribution of the alpha-subunit of the guanine nucleotide-binding protein Gi2 and its comparison to G alpha o.","date":"1989","source":"Journal of receptor research","url":"https://pubmed.ncbi.nlm.nih.gov/2512386","citation_count":11,"is_preprint":false},{"pmid":"37887313","id":"PMC_37887313","title":"Clinical Cases and the Molecular Profiling of a Novel Childhood Encephalopathy-Causing GNAO1 Mutation P170R.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37887313","citation_count":10,"is_preprint":false},{"pmid":"35147852","id":"PMC_35147852","title":"An intronic GNAO1 variant leading to in-frame insertion cause movement disorder controlled by deep brain stimulation.","date":"2022","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/35147852","citation_count":10,"is_preprint":false},{"pmid":"29935962","id":"PMC_29935962","title":"A patient with a GNAO1 mutation with decreased spontaneous movements, hypotonia, and dystonic features.","date":"2018","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/29935962","citation_count":10,"is_preprint":false},{"pmid":"33358199","id":"PMC_33358199","title":"GNAO1 mutation-related severe involuntary movements treated with gabapentin.","date":"2020","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/33358199","citation_count":10,"is_preprint":false},{"pmid":"18192223","id":"PMC_18192223","title":"Enhanced calcium cycling and contractile function in transgenic hearts expressing constitutively active G alpha o* protein.","date":"2008","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18192223","citation_count":10,"is_preprint":false},{"pmid":"29961512","id":"PMC_29961512","title":"Neonatal epileptic encephalopathy caused by de novo GNAO1 mutation misdiagnosed as atypical Rett syndrome: Cautions in interpretation of genomic test results.","date":"2017","source":"Seminars in pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29961512","citation_count":9,"is_preprint":false},{"pmid":"38358016","id":"PMC_38358016","title":"GNAO1 Mutations Affecting the N-Terminal α-Helix of Gαo Lead to Parkinsonism.","date":"2024","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/38358016","citation_count":8,"is_preprint":false},{"pmid":"36654732","id":"PMC_36654732","title":"GNAO1-related neurodevelopmental disorder: Literature review and caregiver survey.","date":"2022","source":"Epilepsy & behavior reports","url":"https://pubmed.ncbi.nlm.nih.gov/36654732","citation_count":8,"is_preprint":false},{"pmid":"36247896","id":"PMC_36247896","title":"Treating GNAO1 mutation-related severe movement disorders with oxcarbazepine: a case report.","date":"2022","source":"Translational pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/36247896","citation_count":8,"is_preprint":false},{"pmid":"35509770","id":"PMC_35509770","title":"Both subthalamic and pallidal deep brain stimulation are effective for GNAO1-associated dystonia: three case reports and a literature review.","date":"2022","source":"Therapeutic advances in neurological disorders","url":"https://pubmed.ncbi.nlm.nih.gov/35509770","citation_count":8,"is_preprint":false},{"pmid":"35117701","id":"PMC_35117701","title":"BRD9 controls the oxytocin signaling pathway in gastric cancer via CANA2D4, CALML6, GNAO1, and KCNJ5.","date":"2020","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35117701","citation_count":7,"is_preprint":false},{"pmid":"37077890","id":"PMC_37077890","title":"CRISPR/Cas9-generated mouse model with humanizing single-base substitution in the Gnao1 for safety studies of RNA therapeutics.","date":"2023","source":"Frontiers in genome editing","url":"https://pubmed.ncbi.nlm.nih.gov/37077890","citation_count":7,"is_preprint":false},{"pmid":"39897576","id":"PMC_39897576","title":"Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder.","date":"2024","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/39897576","citation_count":6,"is_preprint":false},{"pmid":"39048611","id":"PMC_39048611","title":"Gnao1 is a molecular switch that regulates the Rho signaling pathway in differentiating neurons.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39048611","citation_count":6,"is_preprint":false},{"pmid":"34900204","id":"PMC_34900204","title":"GNAO1 as a Novel Predictive Biomarker for Late Relapse in Hepatocellular Carcinoma.","date":"2021","source":"Journal of healthcare engineering","url":"https://pubmed.ncbi.nlm.nih.gov/34900204","citation_count":5,"is_preprint":false},{"pmid":"35964317","id":"PMC_35964317","title":"[Effective Viral Delivery of Genetic Constructs to Neuronal Culture for Modeling and Gene Therapy of GNAO1 Encephalopathy].","date":"2022","source":"Molekuliarnaia biologiia","url":"https://pubmed.ncbi.nlm.nih.gov/35964317","citation_count":5,"is_preprint":false},{"pmid":"35855141","id":"PMC_35855141","title":"Deep brain stimulation in a young child with GNAO1 mutation - Feasible and helpful.","date":"2022","source":"Surgical neurology international","url":"https://pubmed.ncbi.nlm.nih.gov/35855141","citation_count":5,"is_preprint":false},{"pmid":"35725943","id":"PMC_35725943","title":"DBS emergency surgery for treatment of dystonic storm associated with rhabdomyolysis and acute colitis in DYT-GNAO1.","date":"2022","source":"Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/35725943","citation_count":5,"is_preprint":false},{"pmid":"38215303","id":"PMC_38215303","title":"RNA Interference Effectors Selectively Silence the Pathogenic Variant GNAO1 c.607 G > A In Vitro.","date":"2024","source":"Nucleic acid therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38215303","citation_count":4,"is_preprint":false},{"pmid":"36980817","id":"PMC_36980817","title":"Visual Function in Children with GNAO1-Related Encephalopathy.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36980817","citation_count":4,"is_preprint":false},{"pmid":"38331815","id":"PMC_38331815","title":"The Schwann cell-specific G-protein Gαo (Gnao1) is a cell-intrinsic controller contributing to the regulation of myelination in peripheral nerve system.","date":"2024","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/38331815","citation_count":4,"is_preprint":false},{"pmid":"37705601","id":"PMC_37705601","title":"Phenotypes in children with GNAO1 encephalopathy in China.","date":"2023","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/37705601","citation_count":4,"is_preprint":false},{"pmid":"37034444","id":"PMC_37034444","title":"Dystonic Cerebral Palsy Phenotype Due to GNAO1 Variant Responsive to Levodopa.","date":"2023","source":"Tremor and other hyperkinetic movements (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37034444","citation_count":4,"is_preprint":false},{"pmid":"8897310","id":"PMC_8897310","title":"ADP-ribosylation of G alpha i and G alpha o in pituitary cells enhances their recognition by antibodies directed against their carboxyl termini.","date":"1996","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/8897310","citation_count":4,"is_preprint":false},{"pmid":"11562427","id":"PMC_11562427","title":"Reciprocal modulation of alpha(2A)-adrenoceptor and G(alpha o) protein states as determined by carboxy-terminal mutagenesis of a G(alpha o) protein.","date":"2001","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11562427","citation_count":4,"is_preprint":false},{"pmid":"39580518","id":"PMC_39580518","title":"GNAO1 overexpression promotes neural differentiation of glioma stem-like cells and reduces tumorigenicity through TRIM21/CREB/HES1 axis.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/39580518","citation_count":3,"is_preprint":false},{"pmid":"40337144","id":"PMC_40337144","title":"Novel Mutation at Cys225 in GNAO1-Associated Developmental and Epileptic Encephalopathies: Clinical, Molecular, and Pharmacological Profiling of Case Studies.","date":"2025","source":"MedComm","url":"https://pubmed.ncbi.nlm.nih.gov/40337144","citation_count":3,"is_preprint":false},{"pmid":"35782616","id":"PMC_35782616","title":"Gonadal mosaicism in GNAO1 causing neurodevelopmental disorder with involuntary movements; two additional variants.","date":"2022","source":"Molecular genetics and metabolism reports","url":"https://pubmed.ncbi.nlm.nih.gov/35782616","citation_count":3,"is_preprint":false},{"pmid":"9759923","id":"PMC_9759923","title":"Quantification of human dopamine D2s receptor interactions with G alpha(i,1,2)- and G alpha(o)-proteins.","date":"1998","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/9759923","citation_count":3,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49902,"output_tokens":9849,"usd":0.148721,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20641,"output_tokens":5295,"usd":0.11779,"stage2_stop_reason":"end_turn"},"total_usd":0.266511,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"Gαo is required for the light response of ON bipolar neurons in the retina. In Gαo-null mice, the b-wave of the electroretinogram (representing massed ON bipolar cell responses) was entirely absent, while rod/cone photocurrents (a-wave) were normal, establishing that mGluR6 cascade signaling in ON bipolar cells requires Gαo.\",\n      \"method\": \"Knockout mouse (Gαo-/-), electroretinogram recording\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO mouse with specific cellular phenotype (ERG b-wave loss), replicated across rod- and cone-driven components\",\n      \"pmids\": [\"11124982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Gαo is required for muscarinic inhibition of L-type Ca2+ channels in ventricular myocytes. Gαo-null mice lack muscarinic inhibition of L-type calcium channels, while isoproterenol stimulation and muscarinic regulation of atrial K+ channels remain normal. Other Gα subunits cannot substitute.\",\n      \"method\": \"Homologous recombination knockout mouse, patch-clamp electrophysiology of ventricular myocytes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO mouse, specific electrophysiological phenotype with appropriate controls showing other G proteins unchanged\",\n      \"pmids\": [\"9050846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Gαo (but not Gαq/11 or Gαi1-3) transduces α-adrenoceptor inhibition of Ca2+ current in rat sympathetic (superior cervical ganglion) neurons, as established by microinjection of selective anti-Gαo antibodies which reduced noradrenaline-induced calcium current inhibition.\",\n      \"method\": \"Intraneuronal microinjection of subunit-specific antibodies, electrophysiology\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody microinjection with subunit-selective reagents and appropriate controls for other Gα subunits\",\n      \"pmids\": [\"7932231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Gαo is a direct target of reactive oxygen species (H2O2): H2O2 directly activates purified heterotrimeric Go (but not Gs) in vitro by modifying Gαo (not Gβγ), causing subunit dissociation and liberating free Gβγ, which then activates ERK via PI3K and Src in cardiomyocytes.\",\n      \"method\": \"In vitro GTPγS binding assay with purified Go, subunit-specific analysis, cardiomyocyte signaling assays, Gβγ inhibition\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct biochemical reconstitution with purified protein plus multiple cellular assays showing Gβγ-dependent ERK activation downstream of Gαo modification by ROS\",\n      \"pmids\": [\"11100733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The N-terminus of Gαo binds to the C-terminus of the α1A (P/Q-type, Cav2.1) Ca2+ channel subunit, and this interaction mediates voltage-resistant inhibition of α1A currents. An anti-Gαo N-terminal antiserum, Gαo N-terminal peptide, and α1A C-terminal peptide all attenuated voltage-resistant inhibition, and in vitro binding was demonstrated.\",\n      \"method\": \"In vitro binding assay, peptide competition, antibody inhibition, electrophysiology\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro binding reconstitution with peptide competition plus functional electrophysiology in same study; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"11395521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Gαo is required for vomeronasal sensory neuron function in V2R receptor-expressing (basal layer) neurons. Conditional Gαo deletion from olfactory marker protein-expressing cells eliminated responses to MHC class I antigens, major urinary proteins, exocrine gland-secreting peptide, and N-formylated mitochondrial peptides. Loss of Gαo also abolished male-male territorial aggression and maternal aggression.\",\n      \"method\": \"Cre-loxP conditional knockout, electrophysiology, calcium imaging, behavioral assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with direct electrophysiology and calcium imaging plus behavioral readouts; multiple orthogonal methods\",\n      \"pmids\": [\"21768373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Gαo/i reduces the stability of Rap1GAPII by targeting it for ubiquitination and proteasomal degradation, thereby activating Rap1 and inducing neurite outgrowth downstream of CB1 cannabinoid receptor activation. Proteasomal inhibitor lactacystin blocked Gαo/i-induced Rap1 activation and neurite outgrowth.\",\n      \"method\": \"Dominant-negative Rap1 expression, proteasomal inhibition, siRNA, pertussis toxin treatment, overexpression in Neuro-2A cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal interventions (PTX, lactacystin, siRNA, DN-Rap1) in same study establishing mechanism\",\n      \"pmids\": [\"15657046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CB1 receptor signaling through Gαo/i sequentially activates Rap1 → Ral → Src → Stat3, and also Rac1 → JNK → Stat3, to induce neurite outgrowth in Neuro-2A cells. Dominant-negative constructs of Rap1, Ral, Src, and Stat3 each blocked CB1R-induced neurite outgrowth; Ral-DN blocked Gαo-induced Stat3 activation but not v-Src-induced Stat3 activation.\",\n      \"method\": \"Dominant-negative mutant overexpression, pharmacological inhibitors (SP600125), kinase phosphorylation assays, pertussis toxin\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple DN constructs and inhibitors defining pathway order, single lab\",\n      \"pmids\": [\"16046413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Gαo is required for WNT3a-induced JNK activation in mammalian cells, operating downstream of Frizzled-1 through Dishevelled-1 and Dishevelled-3 (not Dvl-2), and then through RhoA, Rac1, Cdc42, and MEKK1/MEKK4 to JNK. This is distinct from the WNT-β-catenin pathway that requires both Gαo and Gαq.\",\n      \"method\": \"siRNA knockdown epistasis, Dapper1 (Dvl antagonist) expression, dominant-negative small GTPases, chemical inhibitors (SP600125, SB203580), F9 teratocarcinoma cells\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic epistasis experiments with siRNA and DN mutants establishing pathway order; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"18187455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The oncogenic R243H mutation in Gαo renders it constitutively active by accelerating the rate of GDP-to-GTP nucleotide exchange without impairing GTPase activity or GAP sensitivity. The mechanism involves loss of an electrostatic interaction between R243 and E43 in the P-loop. Constitutively active Gαo R243H enhances Src-STAT3 signaling in NIH-3T3 cells.\",\n      \"method\": \"Limited proteolysis assays, nucleotide-binding assays, single-turnover and steady-state GTPase assays, structural analysis, Src-STAT3 signaling readouts in cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple in vitro enzymatic assays (nucleotide binding, GTPase) plus structural analysis and cell-based signaling; single lab but orthogonal biochemical methods\",\n      \"pmids\": [\"21317923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Three common GNAO1 encephalopathy mutations affecting Gly203, Arg209, and Glu246 accelerate GTP uptake and inactivate GTP hydrolysis by displacing Gln205, resulting in constitutive GTP binding. The mutant Gαo proteins fail to adopt the active conformation and display aberrant interactions with signaling partners. Zn2+ restores GTPase activity and cellular interactions of these mutants without affecting wild-type Gαo. Dietary zinc rescues motor function and longevity in a Drosophila GNAO1 encephalopathy model.\",\n      \"method\": \"GTP uptake/hydrolysis assays, high-throughput drug screening, Drosophila in vivo model, biochemical interaction assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro biochemical assays for GTP binding/hydrolysis combined with cellular interaction studies and in vivo Drosophila rescue; multiple orthogonal methods\",\n      \"pmids\": [\"36206333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"De novo mutations in GNAO1 cause epileptic encephalopathy. Mutations predicted to destabilize Gαo fold showed impaired plasma membrane localization. The Gly203Arg substitution (switch II region) impairs GTP binding and/or downstream effector activation. Gαo-mediated inhibition of calcium currents by norepinephrine was reduced in three of four mutants by electrophysiological analysis.\",\n      \"method\": \"Whole-exome sequencing, 3D structural modeling, transient expression with localization studies, electrophysiological analysis of Ca2+ current inhibition\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — structural modeling combined with cellular localization assays and electrophysiology; multiple approaches but structural predictions computational\",\n      \"pmids\": [\"23993195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Gγ13 is coexpressed with Gαo (Gαomicron), Gβ3, and Gβ4 specifically in retinal ON bipolar cells (not OFF bipolar cells), suggesting this specific heterotrimer composition participates in ON bipolar cell signal transduction.\",\n      \"method\": \"Immunohistochemistry, single-cell PCR with cDNA hybridization, transgenic GFP mouse to identify bipolar cell types, patch-clamp confirmation of ON physiology\",\n      \"journal\": \"The Journal of comparative neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-localization by IHC and single-cell PCR in defined cell types; functional link inferred from co-expression rather than direct functional experiment\",\n      \"pmids\": [\"12454992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Gαo and Gαi2 are expressed in separate subsets of VNO sensory neurons and are both enriched in VNO microvilli (the transduction compartment), suggesting involvement in pheromone sensory transduction. Adenylyl cyclase type II is co-expressed in both subsets.\",\n      \"method\": \"Cloning, in situ hybridization, immunohistochemistry in mouse VNO\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — localization by IHC with subcellular enrichment shown, but functional link is inferential; later confirmed by conditional KO study (PMID 21768373)\",\n      \"pmids\": [\"8558259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Voltage-dependent calcium channel β-subunit, in combination with α1 subunits, has a GTPase-activating effect on Gαo in rat frontal cortex membranes. Anti-β-subunit antiserum abolished (-)-BayK 8644-stimulated GTP hydrolysis by Go, and a peptide mimicking the β-subunit binding domain of the channel complex also attenuated this GTPase activation.\",\n      \"method\": \"GTPase assay in cortical membranes, antibody inhibition, peptide competition, dihydropyridine binding\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical GTPase assay in native membranes with antibody and peptide competition; single lab, two approaches\",\n      \"pmids\": [\"7544301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Mu-opioid receptor co-immunoprecipitates with Gαo, Gαi1, and Gαi3 (and to a lesser extent Gαi2) from solubilized rat brain membranes. GTPγS treatment abolished co-immunoprecipitation, indicating the receptor associates with these G proteins in the GDP-bound (inactive) heterotrimer state.\",\n      \"method\": \"Co-immunoprecipitation from solubilized rat brain, [3H]DAMGO binding, GTPγS sensitivity\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — reciprocal co-IP from native tissue with nucleotide sensitivity control; single method\",\n      \"pmids\": [\"10693938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GNAO1 mutations display two distinct functional classes: loss-of-function (LOF, <90% maximal cAMP inhibition) and gain-of-function (GOF, lower EC50 for α2A adrenergic receptor-mediated cAMP inhibition). LOF mutations correlate with epileptic encephalopathy while GOF mutations (G42R, G203R, E246K) and normally-functioning mutants associate with movement disorders.\",\n      \"method\": \"Site-directed mutagenesis, Western blot for protein expression, cAMP inhibition assay in HEK-293T cells co-expressing α2A-adrenergic receptor\",\n      \"journal\": \"Neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cAMP assay across 15 clinical variants with defined readout; single lab but systematic coverage\",\n      \"pmids\": [\"28747448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Gαo interacts with SPTAN1 (α-spectrin, another DEE-associated protein) as identified by co-immunoprecipitation and mass spectrometry. Silencing of Gnao1 attenuated neurite outgrowth and calcium-dependent signaling. GNAO1-deficient brain organoids showed reduced SPTAN1 and Ankyrin-G expression and failed to conduct synchronized firing.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, siRNA knockdown, iPSC-derived brain organoids, calcium imaging, neuronal activity recording\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP/MS identification of binding partner combined with functional KD phenotype; single lab, multiple readouts\",\n      \"pmids\": [\"33107105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Cardiac-specific expression of constitutively active Gαo1* in transgenic mice enhances contractile function, increases L-type Ca2+ channel current density, Ca2+ transients, and cell shortening. Protein phosphatase 1 activity was reduced in Gαo* ventricles and PKA-site phosphorylation of ryanodine receptor and phospholamban was increased, suggesting Gαo* acts via protein phosphatase 1 rather than PKA/cAMP.\",\n      \"method\": \"Transgenic mouse cardiac-specific expression, in vivo cardiac function, patch-clamp electrophysiology, Ca2+ transient measurements, protein phosphatase activity assay, PKA assay, cAMP measurement\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic mouse with constitutively active protein and multiple mechanistic readouts; single lab\",\n      \"pmids\": [\"18192223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"In C. elegans, the N-terminal region of RGS protein EGL-10 determines selective inhibition of GOA-1 (Gαo) vs. EGL-30 (Gαq). The N-terminal fragment localizes to membrane where it complexes with the GGL/RGS fragment via GPB-2 (Gβ subunit), increasing the GGL/RGS fragment abundance and membrane localization. Chimera experiments showed GGL/RGS domain of either RGS can act on either Gα, with the N-terminal region determining selectivity.\",\n      \"method\": \"C. elegans transgenic chimera expression, co-immunoprecipitation, fractionation, in vivo phenotypic assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis with chimeric transgenes plus biochemical co-IP and fractionation; C. elegans GOA-1 is the GNAO1 ortholog\",\n      \"pmids\": [\"12354761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GNAO1 mutations at Gln52 (Gαo[Gln52Pro] and novel Gαo[Gln52Arg]) are deficient in GTP binding and hydrolysis. At the cellular level, the mutants show defective interaction with partner proteins that recognize GDP-loaded or GTP-loaded Gαo, and plasma membrane localization is strongly reduced while Golgi localization persists.\",\n      \"method\": \"Biochemical GTP binding/hydrolysis assays, cellular interaction assays, subcellular fractionation/imaging\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro enzymatic assays combined with cellular localization studies; single lab\",\n      \"pmids\": [\"34685729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Pathogenic GNAO1 mutants gain neomorphic interactions with both Ric8A and Ric8B chaperones, relocalizing them from cytoplasm to Golgi. Normally, Ric8A chaperones Gαi/Gαo/Gαq/Gα12/Gα13 and Ric8B solely chaperones Gαs/Gαolf. Pathogenic mutants show abnormal GTP uptake/hydrolysis, reduced Gβγ and RGS19 interactions, and reduced plasma membrane localization. Strength of Gαo-Ric8B interaction correlates with clinical disease severity.\",\n      \"method\": \"Co-immunoprecipitation, GTP binding/hydrolysis assays, cellular localization imaging, clinical severity correlation\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic characterization of >80 mutants with biochemical and cell biological methods, multiple orthogonal approaches, clinical correlation; rigorous single lab study\",\n      \"pmids\": [\"38874642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GNAO1 G203R and G42R mutations produce strong loss-of-function defects when evaluated as homozygous CRISPR alleles in C. elegans, and also produce dominant-negative effects in heterozygous animals and transgenic overexpression. Experiments in mice confirmed dominant-negative effects of GNAO1 G42R on multiple motor behaviors.\",\n      \"method\": \"CRISPR/Cas9 knockin in C. elegans, transgenic overexpression, heterozygous allele analysis, mouse motor behavioral assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR knockin in two model organisms with defined behavioral readouts; single lab\",\n      \"pmids\": [\"34508586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"C. elegans goa-1 (GNAO1 ortholog) mutants exhibit excessive neurotransmitter release (hypersensitivity to aldicarb) and hyperactive locomotion. Caffeine rescues aberrant motor function primarily through adenosine receptor antagonism.\",\n      \"method\": \"CRISPR/Cas9 knockin in C. elegans, aldicarb assay, automated locomotion analysis, pharmacological rescue with caffeine and selective A2A receptor antagonist istradefylline\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR knockin with defined neurotransmitter release readout and pharmacological dissection; single lab\",\n      \"pmids\": [\"34622282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GNAO1 knockdown reduces Gnao1 expression in the locus coeruleus of morphine-dependent mice, and antisense oligonucleotide-mediated knockdown of Gnao1 reduced naloxone-precipitated withdrawal jumping in B6 mice, establishing a functional role for Gαo in opioid physical dependence.\",\n      \"method\": \"Antisense oligonucleotide knockdown, quantitative PCR, behavioral naloxone-precipitated withdrawal assay in recombinant congenic mouse strains\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antisense knockdown with behavioral functional readout and strain-specific controls; single lab\",\n      \"pmids\": [\"19460419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Gαo negatively regulates Schwann cell differentiation and myelination in the peripheral nervous system. Schwann cell-specific Gnao1 deletion promotes SC differentiation, accelerates remyelination after nerve injury, and increases cAMP and PI3K/AKT activity. Conversely, Gnao1 overexpression in SCs impairs myelination.\",\n      \"method\": \"Schwann cell-specific conditional KO, Gnao1 overexpression transgenic mice, nerve injury/remyelination assay, cAMP measurement, PI3K/AKT signaling, RNA sequencing\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO and overexpression with mechanistic pathway analysis; single lab\",\n      \"pmids\": [\"38331815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NRSF transcriptionally represses cardiac Gαo (Gnao1) expression. Increased cardiac Gαo in NRSF-knockout mice leads to increased surface sarcolemmal L-type Ca2+ channel activity, CaMKII activation, impaired Ca2+ handling, and cardiac dysfunction. Cardiac-specific Gnao1 overexpression alone is sufficient to induce cardiac dysfunction; conversely, Gnao1 knockdown ameliorated dysfunction in heart failure models.\",\n      \"method\": \"Cardiac-specific NRSF-KO mice, dominant-negative NRSF transgenic mice, Gnao1 cardiac-specific overexpression and knockdown, cardiac function measurements, L-type Ca2+ channel activity, CaMKII signaling assays\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain and loss of function in multiple mouse models with mechanistic pathway analysis (L-type Ca2+ channel, CaMKII); multiple orthogonal approaches\",\n      \"pmids\": [\"34875852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The phenotypic differences in GDP affinity and activated conformation between Gαo and Gαi2 upon C-terminal truncation are determined by the N-terminal portion of the protein (upstream of codon 212). Chimera analysis and deletion studies identified three hydrophobic residues (positions 11-13 from C-terminus) that make contact with the N-terminal regions (start of β-strands 1 and 3) to stabilize the C-terminal α-helix and affect nucleotide binding.\",\n      \"method\": \"In vitro synthesis in rabbit reticulocyte lysate, tryptic proteolysis assay for conformation, Gαo/Gαi2 chimeras using conserved BamHI site, GDP/GTP binding assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with chimeras and mutagenesis; single lab, multiple biochemical readouts\",\n      \"pmids\": [\"7727415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The C-terminal -3 position glycine residue of Gαo is critical for productive interaction with and activation by the α2A-adrenoceptor. Mutating this Gly to Glu (as in Gαs) drastically reduced agonist potency (22-150 fold) and altered agonist efficacy at the receptor, demonstrating that the C-terminal -3 position of Gαo constrains a structure favorable for receptor interaction.\",\n      \"method\": \"Site-directed mutagenesis of Gαo C-terminus, [35S]GTPγS binding assay in Sf9 cells expressing α2A-AR, pertussis toxin resistance analysis, receptor binding assays\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with functional GTP binding assay and receptor affinity measurements; single lab\",\n      \"pmids\": [\"11562427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A gain-of-function knock-in mouse (Gnao1+/G184S), carrying a RGS-insensitive mutation that prevents Go GTPase turnoff by RGS proteins, develops rare seizures, increased interictal epileptiform discharges, and strain-dependent premature death. This establishes that constitutive Gαo activation (failure to turn off) contributes to seizure susceptibility.\",\n      \"method\": \"Genomic knock-in mouse, EEG recording, pentylenetetrazol kindling, genetic modifier mapping\",\n      \"journal\": \"Mammalian genome\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knock-in mouse model with EEG phenotyping; single lab, defined gain-of-function mechanism (RGS insensitivity)\",\n      \"pmids\": [\"24700286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Leu→Pro substitutions in the N-terminal α-helix of Gαo (L13P and L23P) uniquely destabilize the N-terminal α-helix, block formation of the heterotrimeric G-protein, and disable activation by GPCRs, without affecting enzymatic activity or overall folding. This is associated with a parkinsonism phenotype distinct from the hyperkinetic movement disorder seen with other GNAO1 mutations.\",\n      \"method\": \"Structural and biochemical analysis of purified mutant proteins, heterotrimer formation assay, GPCR coupling assay, clinical phenotyping\",\n      \"journal\": \"Movement disorders\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical characterization of purified mutant protein with structural analysis and functional GPCR coupling assay; single lab\",\n      \"pmids\": [\"38358016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"An intronic GNAO1 mutation (c.724-8G>A) creates a novel splice acceptor site causing in-frame 6-bp intronic retention (2 amino acid insertion, Pro-Gln) within the switch III region of Gαo. This insertion misconfigures switch III, creating novel interactions with switch II, resulting in increased GTP uptake, defective GTP hydrolysis, and aberrant effector protein interactions, while Gβγ interactions and GPCR coupling remain unchanged.\",\n      \"method\": \"RNA splicing analysis from patient lymphoblastoid cells, molecular biochemical characterization (GTP uptake/hydrolysis), protein interaction assays\",\n      \"journal\": \"Med (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — splice analysis from patient cells with mechanistic biochemical characterization; single lab, multiple assays\",\n      \"pmids\": [\"37001522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The intronic GNAO1 c.724-8G>A variant causes an in-frame 2 amino acid insertion (Thr241_Asn242insProGln) in Gαo. The mutant protein shows no significant difference in expression levels but displays partially shifted localization to the cytoplasm compared to exclusive membrane localization of wild-type Gαo.\",\n      \"method\": \"RNA extraction from patient lymphoblastoid cells, immunoblotting, immunostaining of transfected cells\",\n      \"journal\": \"Neurogenetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, immunostaining for localization without full functional follow-up\",\n      \"pmids\": [\"35147852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"siRNA-mediated depletion of Gnao1 in Neuro2a cells perturbs expression of transcripts associated with Rho GTPase signaling and impairs neurite outgrowth. The G203R variant of Gαo disables growth cone formation in iPSC-derived cortical neurons and disrupts neuro-spherical assembly and phospho-MLC2 polarity in cortical organoids. Rho kinase inhibitor Y27632 restores these morphological phenotypes, placing Gαo upstream of the Rho-ROCK pathway in neuronal morphogenesis.\",\n      \"method\": \"siRNA knockdown, iPSC-derived cortical neurons and organoids from patient with G203R variant, immunofluorescence for growth cone markers and phospho-MLC2, pharmacological rescue with Y27632\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD in cell line plus patient-derived iPSC model with pharmacological rescue defining pathway; single lab\",\n      \"pmids\": [\"39048611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Human substance P receptor (hSPR) directly activates Gαo (as well as Gαq/11 and Gαs) in CHO cells, as demonstrated by photoaffinity labeling of Gα subunits with [32P]AA-GTP upon hSPR stimulation followed by subunit-specific immunoprecipitation.\",\n      \"method\": \"Photoaffinity labeling with [32P]azidoanilido-GTP, subunit-specific immunoprecipitation\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single photoaffinity labeling experiment; single lab, single method\",\n      \"pmids\": [\"9654151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Five pertussis toxin-sensitive G proteins were purified from bovine brain including two Gαo isoforms (Gαo-I and Gαo-II) with distinct peptide mapping profiles and migration rates. Only Gαo-I is present in NG 108-15 cell membranes.\",\n      \"method\": \"Protein purification, immunochemical characterization, in situ peptide mapping, PAGE\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct protein purification and biochemical characterization of two Gαo isoforms; single study\",\n      \"pmids\": [\"2506013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"ADP-ribosylation by pertussis toxin (IAP) of Gαo occurs at the C-terminal cysteine residue of Gαo, causing conformational changes as evidenced by enhanced immunoreactivity to C-terminal (but not N-terminal) antibodies and increased sensitivity to trypsin proteolysis. The kinetics of Gi/Go ADP-ribosylation parallel the rate of loss of coupling between inhibitory neuroreceptors and adenylyl cyclase.\",\n      \"method\": \"Cholera toxin/IAP ADP-ribosylation in pituitary cells, antibody immunoreactivity assays, trypsin proteolysis, adenylyl cyclase coupling kinetics\",\n      \"journal\": \"Journal of receptor and signal transduction research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — indirect conformational evidence from antibody epitope accessibility; single lab\",\n      \"pmids\": [\"8897310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The GNAO1 R209C mutation in ALL increases GTPase activity and promotes cell proliferation and neoplastic transformation. Combined with ETV6-RUNX1 fusion, R209C activates PI3K/Akt/mTOR signaling. mTORC1 phosphorylates p300 acetyltransferase, which acetylates ETV6-RUNX1 and enhances its transcriptional activity on the GNAO1 R209C promoter, forming a positive feedback loop.\",\n      \"method\": \"Ectopic expression in cell lines, cell proliferation assay, transformation assay, PI3K/Akt/mTOR pathway analysis, p300 phosphorylation/acetylation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell-based assays establishing signaling pathway; single lab, oncology context\",\n      \"pmids\": [\"32898863\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Gαo (encoded by GNAO1) is the most abundant G protein α-subunit in the mammalian brain and is the immediate signal transducer downstream of multiple GPCRs; it mediates inhibition of neuronal N- and L-type Ca2+ channels (via both direct N-terminal interaction with the Cav2.1 C-terminus and Gβγ-dependent mechanisms), couples mGluR6 to ON bipolar cell light responses in the retina, transduces pheromone detection via V2R receptors in the VNO, mediates WNT-JNK planar cell polarity signaling through Dvl1/3 → RhoA/Rac1/Cdc42 → MEKK1/4 → JNK, and promotes neurite outgrowth by targeting Rap1GAPII for proteasomal degradation to activate Rap1 → Ral → Src → Stat3; it is a target of oxidative stress (ROS directly modify Gαo to cause subunit dissociation), negatively regulates Schwann cell myelination by suppressing cAMP and PI3K/AKT, regulates cardiac Ca2+ homeostasis downstream of NRSF, and is regulated by RGS proteins that act as GTPase-activating proteins (GAPs); pathogenic de novo mutations in GNAO1 disrupt GTP binding/hydrolysis, impair plasma membrane localization, and gain neomorphic interactions with Ric8 chaperones, causing a spectrum of pediatric encephalopathies ranging from epileptic encephalopathy (loss-of-function mutations) to hyperkinetic movement disorders (gain-of-function mutations).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GNAO1 encodes Gαo, a pertussis toxin-sensitive heterotrimeric G protein α-subunit that serves as the immediate transducer downstream of numerous neuronal GPCRs and couples receptor activation to ion-channel and cytoskeletal control [#2, #15]. As a guanine-nucleotide switch, Gαo cycles between GDP-bound (receptor-associated, inactive heterotrimer) and GTP-bound active states; its nucleotide-binding conformation is governed by the N-terminal region and switch elements, and its C-terminal -3 glycine constrains productive receptor coupling [#27, #28]. In sensory and neuronal circuits Gαo is functionally non-redundant: it is required for the mGluR6-driven light response of retinal ON bipolar cells [#0], for V2R-receptor-mediated vomeronasal pheromone detection and associated aggression behaviors [#5], and for muscarinic and α-adrenergic inhibition of neuronal and cardiac Ca2+ channels, in part through direct N-terminal binding to the Cav2.1 C-terminus [#1, #2, #4]. Beyond channel modulation, Gαo drives morphogenetic signaling—promoting neurite outgrowth by targeting Rap1GAPII for proteasomal degradation to activate a Rap1→Ral→Src→Stat3 cascade and a parallel Rho-GTPase→JNK arm downstream of CB1 and WNT/Frizzled receptors [#6, #7, #8], and acting upstream of Rho-ROCK to control growth-cone formation and neuronal polarity [#33]. Gαo also negatively regulates Schwann cell myelination by suppressing cAMP and PI3K/AKT [#25] and sets cardiac Ca2+ homeostasis as a transcriptional target of NRSF [#26]. Its GTPase cycle is accelerated by RGS proteins acting as GAPs [#19, #29], and the protein is a direct oxidative-stress sensor, with H2O2 modifying Gαo to drive subunit dissociation and Gβγ-dependent ERK activation [#3]. De novo GNAO1 mutations cause a spectrum of pediatric encephalopathies: loss-of-function alleles that impair plasma-membrane localization and receptor-mediated cAMP/Ca2+ signaling associate with epileptic encephalopathy, whereas gain-of-function and conformation-altering alleles—which accelerate GTP uptake, abolish hydrolysis by displacing the catalytic glutamine, and acquire neomorphic interactions with Ric8 chaperones—associate with hyperkinetic movement disorders, with disease severity correlating with the strength of aberrant Gαo-Ric8B binding [#11, #16, #10, #21]. Distinct N-terminal helix-destabilizing substitutions that block heterotrimer formation produce a parkinsonian phenotype [#30].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Established that Gαo exists as biochemically distinct purifiable isoforms in brain, providing the protein substrate for all subsequent functional work.\",\n      \"evidence\": \"Protein purification and peptide mapping of two Gαo isoforms from bovine brain\",\n      \"pmids\": [\"2506013\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional differences between Gαo-I and Gαo-II not resolved\", \"Tissue distribution of isoforms incomplete\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined how the nucleotide-binding conformation of Gαo is structurally encoded, showing the N-terminal region and specific hydrophobic C-terminal contacts govern GDP affinity and the activated state.\",\n      \"evidence\": \"In vitro chimera and deletion analysis of Gαo/Gαi2 with proteolysis and nucleotide-binding assays\",\n      \"pmids\": [\"7727415\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of the full switch cycle\", \"Did not address GPCR coupling determinants\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrated that Gαo is the non-redundant transducer of receptor-mediated Ca2+ channel inhibition, ruling out substitution by other Gα subunits.\",\n      \"evidence\": \"Gαo-null mouse with patch-clamp of ventricular myocytes and sympathetic neuron antibody microinjection\",\n      \"pmids\": [\"9050846\", \"7932231\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of channel inhibition (direct vs Gβγ) not distinguished here\", \"Effector identity downstream of Gαo unresolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Resolved Gαo's roles in a sensory circuit and as a direct redox sensor, showing it is required for the ON bipolar light response and is activated by H2O2 to liberate signaling Gβγ.\",\n      \"evidence\": \"Gαo-null ERG recordings; in vitro GTPγS binding with purified Go plus cardiomyocyte ERK assays\",\n      \"pmids\": [\"11124982\", \"11100733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Site of oxidative modification on Gαo not mapped\", \"Link between retinal requirement and downstream effectors incomplete\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified a direct physical mechanism for channel modulation and a structural determinant of receptor coupling, mapping Gαo N-terminus to the Cav2.1 C-terminus and the C-terminal -3 glycine to α2A-adrenoceptor activation.\",\n      \"evidence\": \"In vitro binding, peptide competition, electrophysiology, and C-terminal mutagenesis with GTPγS binding\",\n      \"pmids\": [\"11395521\", \"11562427\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of Gαo-Cav2.1 binding unknown\", \"Generality across channel subtypes untested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined a morphogenetic effector pathway, showing Gαo induces neurite outgrowth by degrading Rap1GAPII to activate a Rap1→Ral→Src→Stat3 cascade with a parallel Rac1/JNK arm.\",\n      \"evidence\": \"Dominant-negative constructs, proteasome and pathway inhibitors, siRNA, pertussis toxin in Neuro-2A cells\",\n      \"pmids\": [\"15657046\", \"16046413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which Gαo directs Rap1GAPII ubiquitination unknown\", \"Relevance to in vivo neuronal development not tested here\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Placed Gαo in WNT planar-cell-polarity signaling and cardiac contractile control, defining a Frizzled→Dvl1/3→RhoA/Rac1/Cdc42→MEKK→JNK axis and a constitutively active cardiac phenotype.\",\n      \"evidence\": \"siRNA epistasis with DN GTPases in F9 cells; cardiac-specific constitutively active Gαo1* transgenic mice\",\n      \"pmids\": [\"18187455\", \"18192223\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct Gαo-Dishevelled interaction not biochemically demonstrated\", \"PP1 versus PKA contributions in heart only partially separated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Confirmed the inferred sensory role in vivo and provided the first disease-relevant activating mutation, with conditional KO eliminating V2R responses and the R243H oncogenic mutant accelerating nucleotide exchange.\",\n      \"evidence\": \"Cre-loxP conditional KO with electrophysiology/behavior; limited proteolysis and GTPase assays with structural analysis\",\n      \"pmids\": [\"21768373\", \"21317923\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"VNO transduction effectors downstream of Gαo unmapped\", \"R243H tumor spectrum and physiological relevance limited\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established GNAO1 as a Mendelian encephalopathy gene, linking de novo mutations to impaired membrane localization and reduced receptor-mediated Ca2+ current inhibition.\",\n      \"evidence\": \"Whole-exome sequencing, 3D modeling, localization and electrophysiology of transfected mutants\",\n      \"pmids\": [\"23993195\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural predictions were computational\", \"Genotype-phenotype mapping incomplete at this stage\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided a functional dichotomy underlying clinical heterogeneity, separating loss-of-function (epilepsy) from gain-of-function (movement disorder) GNAO1 variants by cAMP inhibition phenotype.\",\n      \"evidence\": \"Systematic site-directed mutagenesis and cAMP inhibition assays across 15 variants in HEK-293T cells\",\n      \"pmids\": [\"28747448\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single signaling readout (cAMP) used to classify\", \"Mechanism for normally-functioning mutants causing disease unexplained\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extended mechanistic and physiological scope, defining nucleotide-binding defects and mislocalization for Gln52 mutants, an oncogenic R209C PI3K/mTOR feedback loop, and roles in opioid dependence and NRSF-controlled cardiac Ca2+ handling.\",\n      \"evidence\": \"Biochemical GTP assays and localization; cell transformation and signaling assays; antisense KD with withdrawal behavior; cardiac NRSF-KO and Gnao1 gain/loss mouse models\",\n      \"pmids\": [\"34685729\", \"32898863\", \"19460419\", \"34875852\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Partner proteins distinguishing GDP- vs GTP-loaded Gαo not all identified\", \"Causal chain from cardiac Gαo to CaMKII activation partly correlative\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Unified the biochemical and organismal basis of encephalopathy mutations and revealed therapeutic entry points, showing Gln205 displacement causes constitutive GTP binding, dominant-negative behavior in vivo, and rescue by zinc or adenosine-receptor antagonism.\",\n      \"evidence\": \"GTP uptake/hydrolysis assays, drug screening, Drosophila zinc rescue, C. elegans CRISPR knock-ins, mouse behavior, aldicarb assays\",\n      \"pmids\": [\"36206333\", \"34508586\", \"34622282\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Aberrant partner interactions only partially characterized\", \"Mechanism of zinc rescue at atomic resolution unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined how a non-coding GNAO1 mutation produces disease, showing an intronic splice variant inserts two residues into switch III to misconfigure the GTPase machinery while sparing Gβγ and GPCR coupling.\",\n      \"evidence\": \"Patient lymphoblastoid splicing analysis with biochemical GTP and interaction assays\",\n      \"pmids\": [\"37001522\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific effector interactions altered not fully enumerated\", \"In vivo consequences not modeled\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Converged on a neomorphic disease mechanism and refined neuronal and movement-disorder pathophysiology, showing mutant Gαo gains aberrant Ric8A/Ric8B chaperone interactions correlating with severity, acts upstream of Rho-ROCK in neuronal morphogenesis, and produces parkinsonism via heterotrimer-disrupting N-helix substitutions.\",\n      \"evidence\": \"Co-IP of >80 mutants with localization and clinical correlation; iPSC neurons/organoids with Y27632 rescue; biochemical analysis of purified N-helix mutants; Schwann cell conditional KO\",\n      \"pmids\": [\"38874642\", \"39048611\", \"38358016\", \"38331815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How neomorphic Ric8 binding translates to specific clinical features unclear\", \"Therapeutic targeting of mutant-Ric8 interaction untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the diverse loss-of-function, gain-of-function, dominant-negative, and neomorphic biochemical defects map onto the distinct clinical phenotypes (epilepsy, hyperkinetic movement disorder, parkinsonism) and which downstream effector imbalance is the proximate driver of each.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking specific effector dysregulation to each phenotype\", \"Cell-type-specific consequences of mutations not systematically mapped\", \"No demonstrated mutation-targeted therapy in patients\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [9, 10, 14, 27, 37]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 2, 15, 28, 34]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 6, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [11, 20, 21, 32]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [20, 21]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [21, 32]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 5, 8, 15]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [0, 5, 6, 33]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 16, 21, 30, 37]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 7, 25, 33]}\n    ],\n    \"complexes\": [\n      \"heterotrimeric Go (Gαo/Gβ/Gγ)\"\n    ],\n    \"partners\": [\n      \"Cav2.1\",\n      \"RGS19\",\n      \"Ric8A\",\n      \"Ric8B\",\n      \"SPTAN1\",\n      \"Dvl1\",\n      \"Dvl3\",\n      \"GNB3\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}